Quince Therapeutics
NASDAQ: QNCXSouth San Francisco, US · Founded 2012 · California corporation · 3 known investors
Find your way into Quince Therapeutics
726 people in our graph share verified history with the Quince Therapeutics team — schools, employers, funds. One of them is your warm intro.
Paul Kwanunlockedknows Dirk Thye · together at Stanford University (overlapped)
×4knows the team · via University of California, Berkeley
×5knows the team · via Stanford University
×2knows the team · via UCLA
Quince Therapeutics is a biotechnology company developing the AIDE technology platform, a drug/device combination that encapsulates medications into a patient's own red blood cells to improve drug delivery for rare diseases. The company's lead candidate, eDSP, completed a Phase 3 trial for ataxia-telangiectasia in January 2026 but failed to meet its primary efficacy endpoint; the company is now pursuing strategic alternatives including a potential reverse merger and has suspended further development of its product pipeline.
Founders & leadership
Quince Therapeutics was founded in 2012 by Stephen Dominy and Casey Lynch.
SD
Stephen DominyCo-founder
CL
Casey LynchCo-founder
CR
Charles RyaninExecutive
BH
Brendan HannahExecutive
DT
KG
Kristen GafricExecutive
BR
Brigette RobertsinChief Corporate Affairs Officer
Board
DL
David LamondBoard director
IZ
Ilan ZipkinBoard director
UR
Una RyanBoard director
CS
Christopher SennerBoard director
MM
Margi McLoughlinBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$226.2M disclosed across 5 of 6 rounds · 2015–2026
▶$7.4MofferedJun 2026 · 66 investors · BiotechnologyRule 506(b)
▶$7.4MofferedJun 2026 · 66 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David LamondDirector
- Christopher SennerDirector
- Charles RyanExecutive Officer
- Brendan HannahExecutive Officer
- Dirk ThyeExecutive Officer, Director
- Brigette RobertsExecutive Officer, Director
- June BrayDirector
- Offering amount
- $7.4M
- Sales commissions
- $1.8M
- Placement agents
- LifeSci Capital
- First sale
- May 2026
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$114.7MraisedJun 2026 · 27 investors · BiotechnologyRule 506(b)
▶$114.7MraisedJun 2026 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dirk ThyeExecutive Officer, Director
- June BrayDirector
- Brendan HannahExecutive Officer
- Brigette RobertsExecutive Officer, Director
- Charles RyanExecutive Officer
- Christopher SennerDirector
- David LamondDirector
- Offering amount
- $186.4M
- Amount sold
- $114.7M
- Sales commissions
- $7.9M
- Placement agents
- LifeSci Capital
- First sale
- May 2026
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$11.5MraisedJul 2025 · 15 investors · BiotechnologyRule 506(b)
▶$11.5MraisedJul 2025 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Una RyanDirector
- David LamondDirector
- Christopher SennerDirector
- Charles RyanExecutive Officer
- Margi McLoughlinDirector
- June BrayDirector
- Luca BenattiDirector
- Brendan HannahExecutive Officer
- Dirk ThyeExecutive Officer, Director
- Rajiv PatniDirector
- Offering amount
- $21.9M
- Amount sold
- $11.5M
- Sales commissions
- $689.3K
- Placement agents
- Citizens JMP Securities, LLC
- First sale
- Jun 2025
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$84.5MraisedMay 2018 · 36 investors · PharmaceuticalsRule 506(b)
▶$84.5MraisedMay 2018 · 36 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ilan ZipkinDirector
- Roger QuyDirector
- David LamondDirector
- Kristen GafricExecutive Officer
- Margi McLoughlinDirector
- Casey LynchExecutive Officer, Director
- Stephen DominyDirector
- Offering amount
- $85.6M
- Amount sold
- $84.5M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.6MraisedFeb 2017 · 8 investors · PharmaceuticalsRule 506(b)
▶$7.6MraisedFeb 2017 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen A. DominyDirector
- Casey LynchExecutive Officer, Director
- David LamondDirector
- Ilan ZipkinDirector
- Roger QuyDirector
- Margi McLoughlinDirector
- Kristen GafricExecutive Officer
- Offering amount
- $8M
- Amount sold
- $7.6M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$7.9MraisedJan 2016 · 13 investors · PharmaceuticalsRule 506(b)
▶$7.9MraisedJan 2016 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen DominyDirector
- Casey LynchExecutive Officer, Director
- Margi McLoughlinDirector
- Kristen GafricExecutive Officer
- David LamondDirector
- Ilan ZipkinDirector
- Offering amount
- $15.9M
- Amount sold
- $7.9M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$442.2Mvaluation at IPOMay 2019 · $17.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Quince Therapeutics (QNCX) acquires Orphai and secures up to $187M PIPEstocktitan.net · May 2026Frequently asked questions
- What does Quince Therapeutics do?
- Quince Therapeutics is a biotechnology company developing the AIDE technology platform, a drug/device combination that encapsulates medications into a patient's own red blood cells to improve drug delivery for rare diseases. The company's lead candidate, eDSP, completed a Phase 3 trial for ataxia-telangiectasia in January 2026 but failed to meet its primary efficacy endpoint; the company is now pursuing strategic alternatives including a potential reverse merger and has suspended further development of its product pipeline.
- Who founded Quince Therapeutics?
- Quince Therapeutics was founded by Stephen Dominy, Casey Lynch in 2012.
- Who are Quince Therapeutics's investors?
- Quince Therapeutics's investors include Foresite Capital, Sofinnova Partners, Takeda Ventures.
- How much funding has Quince Therapeutics raised?
- Quince Therapeutics has disclosed $226.2M raised across 5 of its 6 known rounds.
- Where is Quince Therapeutics headquartered?
- Quince Therapeutics is headquartered in South San Francisco, US.